US approves Biogen Idec treatment for one type of hemophilia

March 28, 2014 10:34 PM

8 0

Federal regulators Friday approved a long-acting Biogen Idec drug as the first new hemophilia treatment in 17 years, launching a new class of therapies to control and prevent bleeding in people with hemophilia and opening a potentially lucrative new market for Biogen Idec, the largest biotechnology company in Massachusetts.

The drug, called Alprolix, was okayed by the US Food and Drug Administration specifically for adults and children with hemophilia B, one type of the disease. Biogen Idec, based in Cambridge, is expecting an FDA decision by mid-year on an experimental drug based on the same mechanism of action to tre...

Read more

To category page

Loading...